Hepatitis C
Conditions
Keywords
Hepatitis C
Brief summary
The VISN1 VA Hepatitis C Testing and Linkage to Care Quality Improvement project aims to increase the proportion of Veterans tested for HCV in those born between 1945-1965 and in vulnerable, high-risk groups.
Detailed description
The VISN1 VA Hepatitis C Testing and Linkage to Care Quality Improvement project aims to: (1) increase the proportion of Veterans tested for HCV in those born between 1945-1965 and in vulnerable, high-risk groups, (2) Increase linkage to specialized HCV care among VISN 1 VA Veterans diagnosed with HCV infection, and (3) Evaluate whether race, ethnicity, gender, or other markers of social disparity influence completion of HCV testing and linkage to specialty care, and whether disparities are reduced by the planned VISN 1 VA HCV Quality Improvement (QI) program. The central focus is to reduce delays in diagnosis and linkage to treatment evaluation, management of comorbidities and contraindications, and subsequent initiation.
Interventions
The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
Sponsors
VA Office of Research and Development
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Veterans * Born in the period of 1945-1965 (birth cohort) * With an outpatient visit in primary care at a VISN1 facility in FY 2016
Exclusion criteria
* N/A
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HCV Antibody Test | within 30 days of outpatient primary care visit | Number of Participants with HCV Antibody Test |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Baseline Characteristics at Intervention Sites QI Intervention. QI: HCV Testing QI. Baseline characteristics at intervention sites, pre-implementation. | 2,209 |
| Total | 2,209 |
Baseline characteristics
| Characteristic | Baseline Characteristics at Intervention Sites |
|---|---|
| Age, Customized Age <60 | 505 Participants |
| Age, Customized Age >60 | 1704 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 29 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1526 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 654 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 56 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 683 Participants |
| Race (NIH/OMB) White | 1470 Participants |
| Sex: Female, Male Female | 136 Participants |
| Sex: Female, Male Male | 2073 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 2,209 |
| other Total, other adverse events | 0 / 2,209 |
| serious Total, serious adverse events | 0 / 2,209 |
Outcome results
Primary
HCV Antibody Test
Number of Participants with HCV Antibody Test
Time frame: within 30 days of outpatient primary care visit
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quality Improvement Intervention | HCV Antibody Test | 574 Participants |